Market Overview

Analysts Getting More Bullish On ViroPharma Following Friday's 28+% Surge On Takeover Chatter

Related VPHM
Aurinia Pharma Merits Speculative Buy On M&A Appeal; Phase 3 Study Remains Paramount
US Stock Futures Signal Flat Start On Wall Street

ViroPharma (NASDAQ: VPHM) shares are up about three-quarters of a percent Monday morning on the heels of a 28-plus percent move higher on Friday. Traders in the name were responding to chatter the company had received offers from both Sanofi (NYSE: SNY) and Shire (NASDAQ: SHPG).

Monday morning numerous analysts are commenting and raising price targets on ViroPharma.

  • Stifel Nicolaus raised target from $41 to $47, Buy rating maintained.
  • Piper Jaffray target from $37 to $46, Overweight maintained.
  • Oppenheimer target from $35 to $44, Outperform maintained.
  • Mizuho sees value of $45 assuming cost savings if M&A does happen, believes could include a contingent value of $2-3/share related to cinryze.

ViroPharma shares last traded at $39.41.

Latest Ratings for VPHM

Nov 2013Stifel NicolausDowngradesBuyHold
Nov 2013JP MorganDowngradesOverweightNeutral
Nov 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for VPHM
View the Latest Analyst Ratings

Posted-In: Analyst Color News Rumors Price Target M&A Analyst Ratings Movers


Related Articles (SNY + SHPG)

View Comments and Join the Discussion!

Partner Center